Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect.

Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect.
复制标题

DOI:
10.1093/jac/dkq046
复制
发表时间:
2010-05
期刊:
The Journal of antimicrobial chemotherapy
影响因子:
--
通讯作者:
B. Zhai;Henry Zhou;Liangpeng Yang;Jun Zhang;Kathy Jung;C. Giam;Xin Xiang;Xiaorong Lin
B. Zhai;Henry Zhou;Liangpeng Yang;Jun Zhang;Kathy Jung;C. Giam;Xin Xiang;Xiaorong Lin
中科院分区:
其他
文献类型:
--
作者:
B. Zhai;Henry Zhou;Liangpeng Yang;Jun Zhang;Kathy Jung;C. Giam;Xin Xiang;Xiaorong Lin

文献摘要

相似文献

OBJECTIVES The objective of this study was to identify existing clinical compounds that either possess a fungicidal activity alone or can act synergistically with fungistatic antifungals. METHODS We screened a clinical compound library for drugs that exhibited anti-Aspergillus activity. Among selected compounds, the cationic peptide antibiotic polymyxin B was chosen for further characterization because it can be used parenterally and topically. The fungicidal effect of polymyxin B and its synergistic interactions with azole antifungals were tested against a variety of fungal species. The toxicity of the drug combination of polymyxin B and fluconazole was compared with that of each drug alone in mammalian cell cultures. RESULTS We found that polymyxin B possesses a broad-spectrum antifungal activity at relatively high concentrations. However, because of its synergistic interactions with azole antifungals, polymyxin B at much lower concentrations exerts a potent fungicidal effect against Cryptococcus neoformans, Candida albicans and non-albicans Candida species and moulds when combined with azoles. The combination of polymyxin B and fluconazole at concentrations within susceptible breakpoints is particularly potent against C. neoformans isolates, including fluconazole-resistant strains. The drug combination displayed no additional toxicity compared with polymyxin B alone when tested in cell culture. CONCLUSIONS The combination of polymyxin B and fluconazole has the potential to be used in the clinic to treat systemic cryptococcosis. Our findings suggest that combining cationic peptide antibiotics with azole antifungals could provide a new direction for developing novel antifungal therapies.